Evidence map›Paper›PMID 39858096›Full record

ArticleCancers2025

Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center.

Kento Shionoya, Atsushi Sofuni, Shuntaro Mukai, Yoshiya Yamauchi, Takayoshi Tsuchiya, Reina Tanaka, Ryosuke Tonozuka, Kenjiro Yamamoto, Kazumasa Nagai, Yukitoshi Matsunami and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kento ShionoyaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.ORCID 0000-0002-8399-4797
Atsushi SofuniDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Shuntaro MukaiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Yoshiya YamauchiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Takayoshi TsuchiyaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.ORCID 0000-0002-2586-0635
Reina TanakaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Ryosuke TonozukaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Kenjiro YamamotoDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Kazumasa NagaiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Yukitoshi MatsunamiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Hiroyuki KojimaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Hirohito MinamiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Noriyuki HirakawaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Qiang ZhanDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Takao ItoiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bile duct cancerchemotherapydurvalumabendoscopic drainage

Identifiers

PMID39858096
PMCPMC11764297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.